Health Data Research UK - UK Regional Networks
Lead Research Organisation:
Health Data Research UK
Department Name: UNLISTED
Abstract
Health Data Research UK is a UK-wide Institute which brings together a wide variety of organisations across academia, the NHS and wider public sector, charities and industry working in conjunction with the public and patients to use health-related data to make discoveries that can improve health and wellbeing in the UK and globally. These interests and opportunities are brought together through a number of UK Regional Networks based in Cambridge, London, the Midlands, North (of England), Oxford, Scotland, South-West (of England) and Wales and Northern Ireland. These support and ensure that resources and new knowledge is shared across the Institute and that the benefits from the Institute's research reach the whole of the UK population.
Technical Summary
This work is funded by the UKRI Medical Research Council, UKRI Engineering and Physical Sciences Research Council, UKRI Economic and Social Research Council, Department of Health and Social Care, National Institute for Health Research (England), Chief Scientist Office (Scottish Government), Health and Care Research Wales, Public Health Agency HSC (Northern Ireland), British Heart Foundation and Cancer Research UK
HDR UK's core capabilities and capacity is reflected in a number of UK Regional Networks comprising HDR UK Cambridge, HDR UK London, HDR UK Midlands, HDR UK North, HDR UK Oxford, HDR UK Scotland, HDR UK South-West and HDR Wales and Northern Ireland.
HDR UK regional funding has been transformational in promoting joint working between partners. This funding allows the Institute to benefit from the health data science expertise and infrastructure across the UK and globally, working with regional NHS, academic and industrial ecosystems to deliver the Institute’s mission in partnership. The Regional Networks will inform best use of UK-wide local, regional and national data assets and engage researchers across the four nations to ensure that the benefits reach the whole UK population. The Networks will represent the health research data community in their region. They will build and maintain strong links with colleagues in key regional data custodian organisations and facilities, as well as NIHR Biomedical Research Centres, companies, charities and academic groups across the UK.
The UK Regional Networks will:
1. Enhance regional partnership and collaboration with HDR UK that will enable participation in existing and future Driver Programmes and active participation in Infrastructure and Services to address regional and national priorities
2. Work with regional partners including universities, Academic Health Science Networks (AHSNs) and NHS bodies to speed up adoption of health data science innovation into practice
3. Act as a focus of investment leverage for future HDR UK scientific, training and infrastructure.
HDR UK's core capabilities and capacity is reflected in a number of UK Regional Networks comprising HDR UK Cambridge, HDR UK London, HDR UK Midlands, HDR UK North, HDR UK Oxford, HDR UK Scotland, HDR UK South-West and HDR Wales and Northern Ireland.
HDR UK regional funding has been transformational in promoting joint working between partners. This funding allows the Institute to benefit from the health data science expertise and infrastructure across the UK and globally, working with regional NHS, academic and industrial ecosystems to deliver the Institute’s mission in partnership. The Regional Networks will inform best use of UK-wide local, regional and national data assets and engage researchers across the four nations to ensure that the benefits reach the whole UK population. The Networks will represent the health research data community in their region. They will build and maintain strong links with colleagues in key regional data custodian organisations and facilities, as well as NIHR Biomedical Research Centres, companies, charities and academic groups across the UK.
The UK Regional Networks will:
1. Enhance regional partnership and collaboration with HDR UK that will enable participation in existing and future Driver Programmes and active participation in Infrastructure and Services to address regional and national priorities
2. Work with regional partners including universities, Academic Health Science Networks (AHSNs) and NHS bodies to speed up adoption of health data science innovation into practice
3. Act as a focus of investment leverage for future HDR UK scientific, training and infrastructure.
Organisations
- Health Data Research UK (Lead Research Organisation)
- Central Hospital of Bolzano (Collaboration)
- UNIVERSITY OF BRISTOL (Collaboration)
- BT Group (Collaboration)
- University of California (Collaboration)
- University of Warwick (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Uppsala University Hospital (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- ELIXIR (Collaboration)
- German Cancer Research Center (Collaboration)
- NHS ENGLAND (Collaboration)
- Columbia University Medical Center (Collaboration)
- CANCER RESEARCH UK (Collaboration)
- University of Vermont (Collaboration)
- NHS Leicester City CCG (Collaboration)
- Helmholtz Association of German Research Centres (Collaboration)
- Brigham and Women's Hospital (Collaboration)
- Johannes Gutenberg University of Mainz (Collaboration)
- Amazon.com (Collaboration)
- Intermountain Medical Centre (Collaboration)
- Boston University (Collaboration)
- Central European University (Collaboration)
- Wake Forest University (Collaboration)
- NHS Nottingham and Nottinghamshire CCG (Collaboration)
- UNIVERSITY COLLEGE LONDON (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- BLACK COUNTRY INTEGRATED CARE BOARD (Collaboration)
- Erasmus MC (Collaboration)
- NHS Herefordshire CCG (Collaboration)
- Research Data Scotland (Collaboration)
- University of Glasgow (Collaboration)
- Lund University (Collaboration)
- University of Padova (Collaboration)
- National Institute for Health and Care Research (Collaboration)
- NHS Derby and Derbyshire Clinical Commissioning Group (Collaboration)
- University of Rochester (Collaboration)
- Geisinger Medical Centre (Collaboration)
- University of Oxford (Collaboration)
- Baker IDI Heart and Diabetes Institute (Collaboration)
- Albert Einstein College of Medicine (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- Mayo Clinic (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Harvard University (Collaboration)
- CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- British Heart Foundation (BHF) (Collaboration)
- University Medical Center Freiburg (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Cardiology Frankfurt-Sachsenhausen (Collaboration)
- NHS Coventry and Warwickshire Integrated Care Board (Collaboration)
- Malmo University Hospital (Collaboration)
- Medical University of Innsbruck (Collaboration)
- Baylor College of Medicine (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- East Midlands Academic Health Science Network (Collaboration)
- University of Washington (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Human Technopole (Collaboration)
- UNIVERSITY OF BIRMINGHAM (Collaboration)
- Health and Social Care in Northern Ireland (HSCNI) (Collaboration)
- University of Ulm (Collaboration)
- University of Texas Southwestern Medical Center (Collaboration)
Publications
Abrams K
(2024)
Applying Trial Emulation Methods to Population-Scale Linked Electronic Health Records for Individuals with Multiple Long-Term Conditions Whilst Adjusting for Informative Observations
in International Journal of Population Data Science
Akbari P
(2023)
A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiology.
in Nature communications
Allen NE
(2024)
Prospective study design and data analysis in UK Biobank.
in Science translational medicine
Allen S
(2024)
Recommendations for laboratory workflow that better support centralised amalgamation of genomic variant data: findings from CanVIG-UK national molecular laboratory survey.
in Journal of medical genetics
Apergis-Schoute AM
(2024)
Perseveration and Shifting in Obsessive-Compulsive Disorder as a Function of Uncertainty, Punishment, and Serotonergic Medication.
in Biological psychiatry global open science
Atkinson MD
(2023)
The coding of telephone consultations in UK primary care databases: are we picking up all the calls?
in BMC research notes
Aung N
(2023)
Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure.
in JAMA cardiology
Avgerinou C
(2023)
Trends in incidence of recorded diagnosis of osteoporosis, osteopenia, and fragility fractures in people aged 50 years and above: retrospective cohort study using UK primary care data.
in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
| Title | Health Data science Insights podcast |
| Description | Supported Alexia Sampri to secure NIHR Cambridge BRC pump-prime funding (2024) for the successful Podcast series "Health Data science Insights" which is available on Spotify and Apple podcasts. They explore topics like Trusted Research Environments, ethical considerations, AI, and multiomics. |
| Type Of Art | Artistic/Creative Exhibition |
| Year Produced | 2024 |
| Impact | a few health data science researchers have recorded episodes, the full impact is not yet know as episodes are still being released. |
| URL | https://open.spotify.com/show/5C8UU5yoGqIPOlgULAeHTQ |
| Guideline Title | SCORE2 |
| Description | Availability of the updated new health risk calculator SCORE2 an help prevent heart attacks and strokes in people with type 2 diabetes. |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/CVD-and-Diabetes-Guidelines |
| Description | Contributed to several workshop with UKRI and the Wellcome Trust to shape their sustainable funding policies. Loic Lannelongue |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Contribution to NICE Falls Guideline Development |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Guideline implementation will have major impact on falls prevention |
| Description | Data for Cancer Risk - Scientific Consultation Workshop (John Danesh) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Future use of Whole-Population Electronic Health Records for Research |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Description | HDRUK Wales and the Welsh Criminal Justice Board |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Part of the expert advisory board for the UKRI Net Zero Digitar Research Infrastrure scoping project. Loic Lannelongue |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Participation in NIHR-BHF project COVIDITY-COHORT (John Danesh) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.bhf.org.uk/for-professionals/information-for-researchers/national-flagship-projects |
| Description | Requirement by the French DEFRA to use our Green Algorithms calculator to apply to one of their AI funding calls. Loic Lannelongue |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Teaching on MPhil course, Research Skills MPhil PHS, Applying for research funding module |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Researchers knowledge related to applying for research funding has increased. |
| Description | Teaching on MPhil course, grant application module |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | WHO Global Consultation on Monkeypox (John Danesh) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | eFI tool cited in Chief Medical Officer's Report on Health in an Ageing Society |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | Influence on commissioning of services for older people |
| Description | eFI2 tool implemented in EMIS primary care electronic health record system |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Support development of proactive, preventative, community-based services for older people, aligned with Government policy |
| Description | eFI2 tool included in NHS England Proactive Care Policy Framework |
| Geographic Reach | National |
| Policy Influence Type | Citation in other policy documents |
| Impact | Support delivery of evidence-based care for older people |
| Description | eFalls tool implemented into the Greater Manchester Care Record for proactive falls prevention services |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Routine, automated identification of people at risk of falls for proactive prevention |
| Description | ADR/ESRC Studentship |
| Amount | £60,000 (GBP) |
| Organisation | Economic and Social Research Council |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 08/2027 |
| Description | ADVANCING PRIMARY PREVENTION STRATEGIES FOR COMPLEX DISEASES |
| Amount | £73,459 (GBP) |
| Organisation | Health Data Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 09/2026 |
| Description | An adaptive-design randomised placebo-controlled trial of baclofen in the treatment of alcohol use disorder in patients with liver cirrhosis (BASIS) |
| Amount | £1,631,187 (GBP) |
| Funding ID | NIHR131129 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2025 |
| Description | BRITISH BURDEN ON CARDIOVASCULAR DISORDERS |
| Amount | £45,359 (GBP) |
| Organisation | Health Data Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Description | Biomedical Data Science Accelerator (BIOMEDASA) - Data Science Leadership Award funded by MRC. NHSA 'in-kind' support leveraged for Dr. Eva Caamaño Gutierrez |
| Amount | £500,000 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2024 |
| End | 12/2026 |
| Description | CARELINK Wales - Comprehensive Analysis of Risk factors and outcomes for vulnerable children through LINKed Welsh data |
| Amount | £508,133 (GBP) |
| Funding ID | NIHR156826 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2027 |
| Description | CARELINK Wales - Comprehensive Analysis of Risk factors and outcomes for vulnerable children through LINKed Welsh data. |
| Amount | £416,569 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Clinical prediction foundation models for individuals with multiple long-term conditions |
| Amount | £615,516 (GBP) |
| Funding ID | EP/Y018192/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 04/2025 |
| Description | Comparison of risk factors for hospitalizations and death from winter infections |
| Amount | £1,900 (GBP) |
| Organisation | Health Data Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 03/2023 |
| Description | Complex Multiple long-term conditions (MLTC) Phenotypes, Trends, and Endpoints (CoMPuTE) |
| Amount | £2,639,404 (GBP) |
| Funding ID | NIHR204406 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 05/2028 |
| Description | Comprehensive geriatric assessment to sustain independence for older people living with heart failure with preserved ejection fraction and frailty |
| Amount | £2,325,945 (GBP) |
| Funding ID | NIHR155936 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 12/2028 |
| Description | Comprehensive geriatric assessment to sustain independence for older people living with heart failure with preserved ejection fraction and frailty |
| Amount | £2,499,192 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 01/2029 |
| Description | Concomitant primary prevention of multiple chronic diseases through data-driven approaches mobilising population-wide longitudinal health records |
| Amount | £2,000,000 (GBP) |
| Funding ID | NIHR303137 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 12/2028 |
| Description | Concomitant primary prevention of multiple chronic diseases through data-driven approaches mobilising population-wide longitudinal health records. |
| Amount | £1,958,101 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 11/2028 |
| Description | Deliberative workshops with public members: establishing trust in the use of synthetic data [DELIMIT] |
| Amount | £120,893 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 01/2025 |
| Description | Dementia Capacity Building Post-Doctoral Training Programme |
| Amount | £360,000 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 03/2026 |
| Description | Designing and pilot testing an anticholinergic medication index clinical decision support system (ACMI-CDSS) for use in hospitals to support safer prescribing for older people at risk of medication-related harm |
| Amount | £249,991 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2025 |
| End | 04/2028 |
| Description | Development of methods to identify digitally excluded older people, and tailoring of interventions to meet their digital needs |
| Amount | £412,252 (GBP) |
| Organisation | The Dunhill Medical Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 08/2026 |
| Description | EFFICIENT AI TOOLS FOR EQUITABLE HANDLING OF MISSING VALUES IN POPULATION -WIDE E_HEALTH RECORDS TO ADVANCE PREVENTION OF CHRONIC DISEASE |
| Amount | £605,720 (GBP) |
| Funding ID | G122409 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 03/2025 |
| Description | Efficient AI tools for equitable handling of missing values in population-wide e-health records to advance prevention of chronic diseases |
| Amount | £618,984 (GBP) |
| Funding ID | EP/Y017757/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 04/2025 |
| Description | Embedding public involvement and engagement in the Translational Data Science. |
| Amount | £10,000 (GBP) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 04/2025 |
| Description | Extracting and curating a Cardiovascular eHospital Research Database (eCamCVD) from Cambridge University Hospitals |
| Amount | £27,302 (GBP) |
| Funding ID | RG96157 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 09/2024 |
| Description | Genetic, behavioural and clinical predictors of suboptimal response to statin therapy: a pilot study |
| Amount | £26,534 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 09/2024 |
| Description | Impact and inequalities of winter pressures in primary care: providing the evidence base for mitigation strategies |
| Amount | £2,200,000 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 02/2027 |
| Description | Impact of COVID-19 on the association between Type 2 diabetes and incidence of cardiovascular diseases |
| Amount | £49,928 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Description | Impact of social, economic, and demographic factors in disparity in clinical coding of long COVID in national electronic health records |
| Amount | £92,970 (GBP) |
| Funding ID | 2934825 |
| Organisation | Economic and Social Research Council |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2025 |
| End | 07/2028 |
| Description | Integrating genomic, multi-omic and clinical data at population scale to inform therapeutic targets and drug development programmes |
| Amount | £104,224 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 09/2027 |
| Description | Integration of polygenic risk scores and clinical data into an open platform that enables pragmatic trials |
| Amount | £660,053 (GBP) |
| Funding ID | 227566/Z/23/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 09/2028 |
| Description | Investigating transportablility of cancer detection models across datasets and time using population-wide electronic health data |
| Amount | £90,175 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 12/2023 |
| Description | Large-scale integrative molecular studies of CVDs in multi-ethnic cohorts |
| Amount | £1,749,971 (GBP) |
| Funding ID | RG/F/23/110103 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 02/2029 |
| Description | Leeds Institute for Data Analytics (LIDA) - Data Science Leadership Award fund by MRC. NHSA 'in-kind' support leveraged for Prof. David Westhead |
| Amount | £500,000 (GBP) |
| Organisation | University of Leeds |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2024 |
| End | 08/2027 |
| Description | Linking primary and secondary care data to develop Connected South Yorkshire- NHSE (SNSDE Development Fund)- PI Suzanne Mason |
| Amount | £178,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2024 |
| End | 01/2025 |
| Description | Longitudinal metabolomic profiles and cardiometabolic diseases |
| Amount | £49,950 (GBP) |
| Funding ID | RG96157 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2023 |
| End | 09/2024 |
| Description | MIREDA (Mother and Infant Research Electronic Data Analysis) Partnership |
| Amount | £1,236,698 (GBP) |
| Funding ID | MR/X02055X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2023 |
| End | 06/2026 |
| Description | MRC Health collaboration with the Helmholtz Association |
| Amount | £398,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2023 |
| Description | Maximising independence for older people across community and hospital settings |
| Amount | £2,000,000 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2024 |
| End | 11/2029 |
| Description | Mixed methods study to understand the scale impact and care trajectory for patients who have long lie after a fall. |
| Amount | £731,909 (GBP) |
| Funding ID | NIHR158676 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 06/2026 |
| Description | Molecular Profiles and Genetic Origins of Ancestral Phenotypic Diversity |
| Amount | £8,872 (GBP) |
| Funding ID | G111911 |
| Organisation | Lupus Research Alliance |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 04/2023 |
| End | 04/2026 |
| Description | NIHR Pre-doctoral Fellowship Round 6 |
| Amount | £80,945 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2024 |
| End | 04/2026 |
| Description | NIHR YH Applied Research Centre extension- Professor Suzanne Mason |
| Amount | £1,800,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2024 |
| End | 01/2026 |
| Description | Northern Health Futures Hub |
| Amount | £3,359,256 (GBP) |
| Funding ID | EP/X031012/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2023 |
| End | 10/2026 |
| Description | Optimising Structured Medication Reviews for Older People with Severe Frailty and Care Home Residents to Reduce Overprescribing and Associated Inequalities |
| Amount | £1,035,007 (GBP) |
| Funding ID | NIHR153660 |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2024 |
| End | 12/2026 |
| Description | Optimising Structured Medication Reviews for Older People with Severe Frailty and Care Home Residents to Reduce Overprescribing and Associated Inequalities |
| Amount | £1,101,622 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2023 |
| End | 10/2026 |
| Description | Optimising structured medication reviews for older people with severe frailty and care home residents to reduce overprescribing and associated inequalities |
| Amount | £1,016,222 (GBP) |
| Organisation | National Institute for Health and Care Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2024 |
| End | 10/2026 |
| Description | PANORAMA: Pan-North Data Research Advancements for Multi-domain Access and Analysis funded by Dare UK. NHSA 'in-kind' support leveraged for Dr. Kate O'Sullivan |
| Amount | £400,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2024 |
| End | 03/2026 |
| Description | Professor Andy Clegg NIHR funded grant: Dementia Capacity Building Post-Doctoral Training Programme |
| Amount | £360,000 (GBP) |
| Organisation | University of Leeds |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 03/2026 |
| Description | Professor Andy Clegg NIHR grant: Maximising independence for older people across community and hospital settings |
| Amount | £2,000,000 (GBP) |
| Organisation | University of Leeds |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2024 |
| End | 11/2029 |
| Description | Professor Munir Sir Pirmohamed Award: Self-funded studentship titled 'A data-driven approach to identifying and characterising adverse drug reaction' |
| Amount | £120,000 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2024 |
| End | 09/2028 |
| Description | Professor Sir Munir Pirmohamed Funded grant by European Commission titled 'ARDAT: Accelerating Research & Development for Advanced Therapies' |
| Amount | £167,261 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 04/2025 |
| Description | Professor Sir Munir Pirmohamed NIHR funded grant titled 'Alcohol Use Disorder and Organ Related Complications' |
| Amount | £758,725 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 11/2027 |
| Description | Professor Sir Munir Pirmohamed funded grant funded by Innovate UK titled 'UK Regulatory Science and Innovation Network in Pharmacogenomics' |
| Amount | £50,000 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 08/2024 |
| Description | Professor Suzanne Mason NHSE, Data for R&D Programme- Network Driver Project: Using routine data to identify patients at risk of long hospital stay. |
| Amount | £300,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2024 |
| End | 03/2025 |
| Description | Reducing Avoidable Admissions in Acute Hospital Care: The role and impact of Same Day Emergency Care Services. Funded by NIHR HSDR. Co-I Professor Suzanne Mason |
| Amount | £918,000 (GBP) |
| Organisation | University of Sheffield |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2024 |
| End | 10/2027 |
| Description | The South Yorkshire Digital Health Hub |
| Amount | £3,211,469 (GBP) |
| Funding ID | EP/X03075X/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 08/2026 |
| Description | The effect of the COVID-19 pandemic on outcomes in pregnant women with pre-existing cardiovascular disease |
| Amount | £49,070 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Description | The first England-wide study of pregnant women with pre-existing heart disease: the impact of COVID-19 diagnosis and vaccination |
| Amount | £49,070 (GBP) |
| Organisation | Health Data Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Description | Translational proteomics for cardiovascular diseases: from population prediction to clinical and therapeutic applications (Prot4CVD) (joint funding with DZHK and DHF) |
| Amount | £490,874 (GBP) |
| Funding ID | SP/F/23/150048 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 03/2027 |
| Description | UK Centre of Excellence on In-Silico Regulatory Science and Innovation (UK CEiRSI) - Discovery Phase funded by Innovate UK. NHSA 'in-kind' support leveraged for Prof. Alex Frangi |
| Amount | £50,000 (GBP) |
| Organisation | University of Manchester |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 08/2024 |
| Description | Validation of SCORE2 10-year cardiovascular disease risk prediction models before and after the Covid-19 pandemic in the population of England |
| Amount | £49,228 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Description | Wellbeing in later life in Bradford: a risk stratified longitudinal cohort study |
| Amount | £892,518 (GBP) |
| Organisation | Nuffield Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2024 |
| End | 09/2028 |
| Title | Atlas for Health |
| Description | Disease Atlas is an ambitious project involving the generation of systematic, data-driven knowledge across all common and rare diseases. Using newly available nationwide data on 56 million people the Atlas is generating novel comparative insights of the health needs of patients, the care provided, and the research that is carried out (Figure). We believe that the Disease Atlas may change the way we think about and research diseases, inform policy and practice and unlock new ways to improve the health of patients and communities. The Atlas is based on learning from linked, longitudinal and nationwide data made available to support the COVID-19 pandemic response. A dominant paradigm in health research is to study one disease, or one group of diseases at a time. Moreover diseases which are considered 'rare' are usually researched separately from those considered common. Patients and clinicians recognize two limitations of this paradigm: first it misses out on the experience of people (patients), who commonly have multiple diseases, and may take multiple medications; and second, it is not systematic, and many diseases and populations are relatively neglected in research. The Atlas is still in development |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | still in development |
| URL | https://www.ucl.ac.uk/health-informatics/research/disease-atlas |
| Title | SCORE2 Diabetes (HDRUK Cambridge) |
| Description | . The SCORE2-Diabetes cardiovascular risk prediction model was published by HDR UK Cambridge researchers (https://academic.oup.com/eurheartj/article/44/28/2544/7185610). This new, calibrated algorithm will enhance identification of individuals at higher risk of developing cardiovascular disease across Europe, and will help inform public health policy. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | SCORE2-Diabetes, a new algorithm developed, calibrated, and validated to predict 10-year risk of CVD in individuals with type 2 diabetes, enhances identification of individuals at higher risk of developing CVD across Europe. |
| URL | https://academic.oup.com/eurheartj/article/44/28/2544/7185610 |
| Title | Ageing Research Trials (ART) Repository |
| Description | ART repository of ageing research trial data for individual participant data meta-analysis (IPDMA) |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | Global first repository for ageing research trials |
| Title | HDR UK South West -Data Catalogue for UKLLC -UKLLC Explore |
| Description | UK LLC has launched its data catalogue able to build data to specification, UK LLC Explore, and descriptive data dictionary, UK LLC Guidebook; the UK LLC Resource Hub has been released and will soon be made publicly available. Contractual arrangements with ONS (data controller) and DWP and HMRC (data owners) have been signed. ONS is already building the UK LLC linkage and processing pipeline to minimise the impact of delays; we anticipate this to be tested within 2024. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | ongoing |
| URL | https://explore.ukllc.ac.uk/ |
| Title | UK Longitudinal Linkage Collaboration |
| Description | The UK Longitudinal Linkage Collaboration (UK LLC) is the national Trusted Research Environment for longitudinal research. Led by the Universities of Bristol and Edinburgh, in collaboration with UCL, SeRP UK, Swansea University and the University of Leicester, it is a collaborative endeavour with many of the UK's most established longitudinal studies. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Currently 29 projects approved to access and use linked cohort and EHR data within the UKLLC. https://ukllc.ac.uk/data-use-register 4 x publications from projects utilising UK LLC data https://ukllc.ac.uk/publication-data |
| URL | https://ukllc.ac.uk/ |
| Title | eCamCVD Database (HDRUK Cambridge) |
| Description | eCamCVD comprises person-level data from Cambridge University Hospitals electronic health records (EHR) for patients receiving medical care related to cardiovascular disease. The EHR includes, but is not limited to, data from the electronic hospital notes system (Epic), the imaging system (PACS), and other relevant hospital informant systems. The database will include person-level structured data on demographics, length of hospital stay, in-hospital deaths, diagnoses, procedures, imaging, pathology reports, laboratory results, physical measurements and vital signs, clinical referrals and patient medications prior to admission, during admission and on discharge from hospital, as well as on outpatient, emergency department and critical care episodes. eCamCVD will be available for bona fide UK researchers to access |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | The eCamCVD database is an excellent example of partnership with multiple organisations (Cambridge University Hospitals Trust; the East of England sub-national Secure Data Environment (SDE); the Cambridge Mathematics of Information in Healthcare Hub; the BHF Cambridge Centre for Research Excellence; the NIHR Cambridge Biomedical Research Centre), and leveraged support from some of these organisations, resulting in an enduring resource for the UK research community. eCamCVD is a driver project in the East of England sub-national SDE. |
| Description | British Heart Foundation-HDR UK National Cardiovascular Data Science Centre |
| Organisation | British Heart Foundation (BHF) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | As member of Scientific Steering Group gave invited talk at workshop (phenomics) and advised on priorities |
| Collaborator Contribution | £10M |
| Impact | Academic, research and clinical outputs |
| Start Year | 2019 |
| Description | CD3 and HDRUK Oxford |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The HDRUK Oxford team have contributed to the formation of a new collaboration between Cancer Research UK, NHS England and Health Data Research UK (the CD3 initiative) which aims to leverage the UK's population-scale electronic health record infrastructure and its strengths in cancer multi-omics, epidemiology, advanced analytics, as well as its participatory approach to research. |
| Collaborator Contribution | Expertise, leadership |
| Impact | none as yet |
| Start Year | 2023 |
| Description | ECHILD study and HDRUK Cambridge |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Cambridge is collaborating with UCL via the Social and Environmental determinants of Health programme, where the common goal is to enhance Genomics England and eCHILD datasets to better understand developmental disorders. |
| Collaborator Contribution | genomic and health data linkage expertise |
| Impact | none as yet |
| Start Year | 2023 |
| Description | EMBL EBI and HDRUK Cambridge |
| Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Dr Helen Parkinson is part of the leadership team for the HDR UK Phenotype library led by HDRUK Cambridge. Her department at EMBL-EBI also continues to bring significant leveraged support to HDR UK Cambridge, e.g. through core-funded staff contributions, cloud infrastructure, and grant funding that helps support specific HDR UK projects |
| Collaborator Contribution | Leveraging grant funding, expertise |
| Impact | NA |
| Start Year | 2023 |
| Description | Genomic Medicine collaboration |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Human Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration forms a work-stream in the HDR UK Molecules to Health Records driver programme, and aims to understand causes of neurodevelopmental disorders better. I provide overall leadership for the programme. |
| Collaborator Contribution | The collaboration comprises researchers from the University of Oxford (led by Professor Stephan Sanders), the Wellcome Sanger Institute (led by Professor Matt Hurles), UCL (led by Professor Ruth Gilbert), and the University of Cambridge (led by Dr Richard Bethlehem). These partners bring multi-disciplinary expertise (described below), as well as leadership of specific data resources that will be used for this research (e.g. ECHILD, Deciphering Developmental Disorders, NHS neuro-imaging data). All partners will contribute to creating a novel, multi-dimensional data resource, and the analysis of these data. |
| Impact | No outcomes thus far. The collaboration is multi-disciplinary, comprising: Sanders group - paediatric neurogenetics Hurles group - genetics of developmental disorders Gilbert group - social epidemiology Bethlehem group - neuroinformatics and neuroimaging |
| Start Year | 2023 |
| Description | Genomic Medicine collaboration |
| Organisation | University College London |
| Department | Institute of Child Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration forms a work-stream in the HDR UK Molecules to Health Records driver programme, and aims to understand causes of neurodevelopmental disorders better. I provide overall leadership for the programme. |
| Collaborator Contribution | The collaboration comprises researchers from the University of Oxford (led by Professor Stephan Sanders), the Wellcome Sanger Institute (led by Professor Matt Hurles), UCL (led by Professor Ruth Gilbert), and the University of Cambridge (led by Dr Richard Bethlehem). These partners bring multi-disciplinary expertise (described below), as well as leadership of specific data resources that will be used for this research (e.g. ECHILD, Deciphering Developmental Disorders, NHS neuro-imaging data). All partners will contribute to creating a novel, multi-dimensional data resource, and the analysis of these data. |
| Impact | No outcomes thus far. The collaboration is multi-disciplinary, comprising: Sanders group - paediatric neurogenetics Hurles group - genetics of developmental disorders Gilbert group - social epidemiology Bethlehem group - neuroinformatics and neuroimaging |
| Start Year | 2023 |
| Description | Genomic Medicine collaboration |
| Organisation | University of Cambridge |
| Department | Department of Psychology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration forms a work-stream in the HDR UK Molecules to Health Records driver programme, and aims to understand causes of neurodevelopmental disorders better. I provide overall leadership for the programme. |
| Collaborator Contribution | The collaboration comprises researchers from the University of Oxford (led by Professor Stephan Sanders), the Wellcome Sanger Institute (led by Professor Matt Hurles), UCL (led by Professor Ruth Gilbert), and the University of Cambridge (led by Dr Richard Bethlehem). These partners bring multi-disciplinary expertise (described below), as well as leadership of specific data resources that will be used for this research (e.g. ECHILD, Deciphering Developmental Disorders, NHS neuro-imaging data). All partners will contribute to creating a novel, multi-dimensional data resource, and the analysis of these data. |
| Impact | No outcomes thus far. The collaboration is multi-disciplinary, comprising: Sanders group - paediatric neurogenetics Hurles group - genetics of developmental disorders Gilbert group - social epidemiology Bethlehem group - neuroinformatics and neuroimaging |
| Start Year | 2023 |
| Description | Genomic Medicine collaboration |
| Organisation | University of Oxford |
| Department | Department of Paediatrics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This collaboration forms a work-stream in the HDR UK Molecules to Health Records driver programme, and aims to understand causes of neurodevelopmental disorders better. I provide overall leadership for the programme. |
| Collaborator Contribution | The collaboration comprises researchers from the University of Oxford (led by Professor Stephan Sanders), the Wellcome Sanger Institute (led by Professor Matt Hurles), UCL (led by Professor Ruth Gilbert), and the University of Cambridge (led by Dr Richard Bethlehem). These partners bring multi-disciplinary expertise (described below), as well as leadership of specific data resources that will be used for this research (e.g. ECHILD, Deciphering Developmental Disorders, NHS neuro-imaging data). All partners will contribute to creating a novel, multi-dimensional data resource, and the analysis of these data. |
| Impact | No outcomes thus far. The collaboration is multi-disciplinary, comprising: Sanders group - paediatric neurogenetics Hurles group - genetics of developmental disorders Gilbert group - social epidemiology Bethlehem group - neuroinformatics and neuroimaging |
| Start Year | 2023 |
| Description | HDR UK Midlands Health Data Strategy Board |
| Organisation | NHS Nottingham and Nottinghamshire CCG |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | HDR UK Midlands have established The Midlands Health Data Strategy Board, helping to position our region at the forefront of health data innovation. The inaugural board meeting, scheduled for November 2024, marks the beginning of a transformative era in regional health data strategy. |
| Collaborator Contribution | Strategic Direction: Defining a vision that aligns with both regional and national health data priorities. Stakeholder Engagement: Building connections with national and regional stakeholders to reinforce the Midlands' position as a leader in health data science. Programme Monitoring: Overseeing HDR UK Midlands initiatives to ensure objectives and performance targets are met. Problem-Solving: Identifying risks and challenges, fostering collaboration to find innovative solutions. |
| Impact | ongoing - multidisiplinary; clinical, NHS policymakers, patient representatives, local data science and infrastructure expertise |
| Start Year | 2024 |
| Description | HDR UK Midlands Health Data Strategy Board |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Midlands have established The Midlands Health Data Strategy Board, helping to position our region at the forefront of health data innovation. The inaugural board meeting, scheduled for November 2024, marks the beginning of a transformative era in regional health data strategy. |
| Collaborator Contribution | Strategic Direction: Defining a vision that aligns with both regional and national health data priorities. Stakeholder Engagement: Building connections with national and regional stakeholders to reinforce the Midlands' position as a leader in health data science. Programme Monitoring: Overseeing HDR UK Midlands initiatives to ensure objectives and performance targets are met. Problem-Solving: Identifying risks and challenges, fostering collaboration to find innovative solutions. |
| Impact | ongoing - multidisiplinary; clinical, NHS policymakers, patient representatives, local data science and infrastructure expertise |
| Start Year | 2024 |
| Description | HDR UK Midlands Health Data Strategy Board |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Midlands have established The Midlands Health Data Strategy Board, helping to position our region at the forefront of health data innovation. The inaugural board meeting, scheduled for November 2024, marks the beginning of a transformative era in regional health data strategy. |
| Collaborator Contribution | Strategic Direction: Defining a vision that aligns with both regional and national health data priorities. Stakeholder Engagement: Building connections with national and regional stakeholders to reinforce the Midlands' position as a leader in health data science. Programme Monitoring: Overseeing HDR UK Midlands initiatives to ensure objectives and performance targets are met. Problem-Solving: Identifying risks and challenges, fostering collaboration to find innovative solutions. |
| Impact | ongoing - multidisiplinary; clinical, NHS policymakers, patient representatives, local data science and infrastructure expertise |
| Start Year | 2024 |
| Description | HDR UK Midlands Health Data Strategy Board |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Midlands have established The Midlands Health Data Strategy Board, helping to position our region at the forefront of health data innovation. The inaugural board meeting, scheduled for November 2024, marks the beginning of a transformative era in regional health data strategy. |
| Collaborator Contribution | Strategic Direction: Defining a vision that aligns with both regional and national health data priorities. Stakeholder Engagement: Building connections with national and regional stakeholders to reinforce the Midlands' position as a leader in health data science. Programme Monitoring: Overseeing HDR UK Midlands initiatives to ensure objectives and performance targets are met. Problem-Solving: Identifying risks and challenges, fostering collaboration to find innovative solutions. |
| Impact | ongoing - multidisiplinary; clinical, NHS policymakers, patient representatives, local data science and infrastructure expertise |
| Start Year | 2024 |
| Description | HDR UK Midlands Health Data Strategy Board |
| Organisation | University of Warwick |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Midlands have established The Midlands Health Data Strategy Board, helping to position our region at the forefront of health data innovation. The inaugural board meeting, scheduled for November 2024, marks the beginning of a transformative era in regional health data strategy. |
| Collaborator Contribution | Strategic Direction: Defining a vision that aligns with both regional and national health data priorities. Stakeholder Engagement: Building connections with national and regional stakeholders to reinforce the Midlands' position as a leader in health data science. Programme Monitoring: Overseeing HDR UK Midlands initiatives to ensure objectives and performance targets are met. Problem-Solving: Identifying risks and challenges, fostering collaboration to find innovative solutions. |
| Impact | ongoing - multidisiplinary; clinical, NHS policymakers, patient representatives, local data science and infrastructure expertise |
| Start Year | 2024 |
| Description | HDR UK NI Advancement of Northern Ireland Trusted Research Environment (NITRE) |
| Organisation | Health and Social Care in Northern Ireland (HSCNI) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Development across Digital Health and Care NI to further advance the NI Trusted Research Environment (NI TRE) with regular NITRE Advisory Board meetings |
| Collaborator Contribution | health and care data expertise, infrastructure, clinical and academic |
| Impact | • Time Limited Memorandum of Understanding (MOU) signed with Health and Social Care Northern Ireland (HSC-NI), mediated through the Northern Ireland Data Institute • A series of seven projects, exploring the development and provision of solutions to store legacy data commenced with HSC-NI • Regular meetings with HDR UK Regional Networks • Deploying data from the General Practice Intelligence Platform (GPIP) to look at prevalence of COPD and Asthma in Northern Ireland. This four nation study is part of the Inflammation and Immunity Research Driver Programme • Exploring how best to deploy Common Data Models for NI/all island data with HDR Infrastructure |
| Start Year | 2024 |
| Description | HDR UK NI collaboration with BT /AWS |
| Organisation | Amazon.com |
| Department | Amazon Web Services |
| Country | United States |
| Sector | Private |
| PI Contribution | Scientific and regional data expertise to inform driver use cases: Specific technical use-cases being planned with hyperscalers Microsoft and British Telecom/AWS • Bidirectional sharing of genomics data between Queen's and HSC-NI - key for creation of connected ecosystem • Pilot for Genomics production workflows to support Genomics research • Cross border connection of cancer patient data - embedded in disease specific use cases • BT-AWS Agreed to create cross border SDE • Three core disease use cases identified - closely aligned with HDR NI and Al, Island e-Health Hub for Cancer • Colorectal - EPI700 cohort as initial focus and creation of new digital population based cohorts • Prostate - FastMan Radiation response cohort, with focus on connecting to real-world real-time data for monitoring outcomes and impact of radiotherapy • Childhood Cancers at earlier stage - creation of All Island childhood cancer genomics and research Network - meeting 10th December 2024 in Dublin |
| Collaborator Contribution | scientific, clinical, regional data and infrastructure expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDR UK NI collaboration with BT /AWS |
| Organisation | BT Group |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Scientific and regional data expertise to inform driver use cases: Specific technical use-cases being planned with hyperscalers Microsoft and British Telecom/AWS • Bidirectional sharing of genomics data between Queen's and HSC-NI - key for creation of connected ecosystem • Pilot for Genomics production workflows to support Genomics research • Cross border connection of cancer patient data - embedded in disease specific use cases • BT-AWS Agreed to create cross border SDE • Three core disease use cases identified - closely aligned with HDR NI and Al, Island e-Health Hub for Cancer • Colorectal - EPI700 cohort as initial focus and creation of new digital population based cohorts • Prostate - FastMan Radiation response cohort, with focus on connecting to real-world real-time data for monitoring outcomes and impact of radiotherapy • Childhood Cancers at earlier stage - creation of All Island childhood cancer genomics and research Network - meeting 10th December 2024 in Dublin |
| Collaborator Contribution | scientific, clinical, regional data and infrastructure expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDR UK NI collaboration with UK SeRP |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | NI Honest Broker Service hosted on UK SeRP infrastructure at Swansea University enabling access to UK wide approved researchers for NI population level linked data |
| Collaborator Contribution | Hosting infratstructure, technical expertise |
| Impact | ongoing |
| Start Year | 2020 |
| Description | HDRUK Midlands NHS Digital Leaders Network |
| Organisation | Black Country Integrated Care Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Established a Midlands Chief Clinical Information Officers (CCIO) Network , expanding to 64 members from 52 organisations. Five network meetings have been held within the period, featuring presentations from two CCIOs, The NHS Innovation Accelerator, DEXTER, NHS England and NHS Arden & Greater East Midlands CSU. This network plays a pivotal role in promoting the use of data and driving digital transformation across our region. |
| Collaborator Contribution | Clinical data and information expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDRUK Midlands NHS Digital Leaders Network |
| Organisation | NHS Coventry and Warwickshire Integrated Care Board |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Established a Midlands Chief Clinical Information Officers (CCIO) Network , expanding to 64 members from 52 organisations. Five network meetings have been held within the period, featuring presentations from two CCIOs, The NHS Innovation Accelerator, DEXTER, NHS England and NHS Arden & Greater East Midlands CSU. This network plays a pivotal role in promoting the use of data and driving digital transformation across our region. |
| Collaborator Contribution | Clinical data and information expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDRUK Midlands NHS Digital Leaders Network |
| Organisation | NHS Derby and Derbyshire Clinical Commissioning Group |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Established a Midlands Chief Clinical Information Officers (CCIO) Network , expanding to 64 members from 52 organisations. Five network meetings have been held within the period, featuring presentations from two CCIOs, The NHS Innovation Accelerator, DEXTER, NHS England and NHS Arden & Greater East Midlands CSU. This network plays a pivotal role in promoting the use of data and driving digital transformation across our region. |
| Collaborator Contribution | Clinical data and information expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDRUK Midlands NHS Digital Leaders Network |
| Organisation | NHS Herefordshire CCG |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Established a Midlands Chief Clinical Information Officers (CCIO) Network , expanding to 64 members from 52 organisations. Five network meetings have been held within the period, featuring presentations from two CCIOs, The NHS Innovation Accelerator, DEXTER, NHS England and NHS Arden & Greater East Midlands CSU. This network plays a pivotal role in promoting the use of data and driving digital transformation across our region. |
| Collaborator Contribution | Clinical data and information expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDRUK Midlands NHS Digital Leaders Network |
| Organisation | NHS Leicester City CCG |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Established a Midlands Chief Clinical Information Officers (CCIO) Network , expanding to 64 members from 52 organisations. Five network meetings have been held within the period, featuring presentations from two CCIOs, The NHS Innovation Accelerator, DEXTER, NHS England and NHS Arden & Greater East Midlands CSU. This network plays a pivotal role in promoting the use of data and driving digital transformation across our region. |
| Collaborator Contribution | Clinical data and information expertise |
| Impact | ongoing |
| Start Year | 2024 |
| Description | HDRUK Midlands and Regional NIHR BRCs |
| Organisation | National Institute for Health and Care Research |
| Department | NIHR Nottingham Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Awareness raised amongst community. Joint working across the regional NIHR BRCs and NHS England SDEs. Facilitated by HDR UK Midlands . |
| Collaborator Contribution | Scientific leadership and expertise, opportunities for collaborative working and leveraged funding |
| Impact | Regional BRC's and SDE's presented at annual event. HDR UK Midlands presentation at Nottingham BRC. Joint workshop between HDR Midlands and Birmingham BRC. Lead for Birmingham, Leicester and Nottingham BRCs Associate Director and part of HDR Midlands Leadership Team. |
| Start Year | 2023 |
| Description | HDRUK Midlands and Regional NIHR BRCs |
| Organisation | University of Leicester |
| Department | NIHR Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Awareness raised amongst community. Joint working across the regional NIHR BRCs and NHS England SDEs. Facilitated by HDR UK Midlands . |
| Collaborator Contribution | Scientific leadership and expertise, opportunities for collaborative working and leveraged funding |
| Impact | Regional BRC's and SDE's presented at annual event. HDR UK Midlands presentation at Nottingham BRC. Joint workshop between HDR Midlands and Birmingham BRC. Lead for Birmingham, Leicester and Nottingham BRCs Associate Director and part of HDR Midlands Leadership Team. |
| Start Year | 2023 |
| Description | HDRUK Regional Network and HDRUK London |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK London led a meeting across HDRUK Regional Network to stimulate inter-regional collaboration This included HDRUK North HDRUK Wales, HDRUK South West and HDRUK Midlands. Meetings have focused on our approach to delivering an inter-regional methods pilot focusing on high-cost drug data / climate data. These initial meetings have resulted in grant development meetings and ongoing work to apply for the 2023 NIHR Team Science Award Round 1 - Multiple Long Term Conditions | NIHR grant to take forward work on multi-morbidity and environmental impact of medicines. |
| Collaborator Contribution | Expertise, health data ecosystem and scientific leadership |
| Impact | none yet |
| Start Year | 2023 |
| Description | HDRUK Regional Network and HDRUK London |
| Organisation | University of Birmingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK London led a meeting across HDRUK Regional Network to stimulate inter-regional collaboration This included HDRUK North HDRUK Wales, HDRUK South West and HDRUK Midlands. Meetings have focused on our approach to delivering an inter-regional methods pilot focusing on high-cost drug data / climate data. These initial meetings have resulted in grant development meetings and ongoing work to apply for the 2023 NIHR Team Science Award Round 1 - Multiple Long Term Conditions | NIHR grant to take forward work on multi-morbidity and environmental impact of medicines. |
| Collaborator Contribution | Expertise, health data ecosystem and scientific leadership |
| Impact | none yet |
| Start Year | 2023 |
| Description | HDRUK Regional Network and HDRUK London |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK London led a meeting across HDRUK Regional Network to stimulate inter-regional collaboration This included HDRUK North HDRUK Wales, HDRUK South West and HDRUK Midlands. Meetings have focused on our approach to delivering an inter-regional methods pilot focusing on high-cost drug data / climate data. These initial meetings have resulted in grant development meetings and ongoing work to apply for the 2023 NIHR Team Science Award Round 1 - Multiple Long Term Conditions | NIHR grant to take forward work on multi-morbidity and environmental impact of medicines. |
| Collaborator Contribution | Expertise, health data ecosystem and scientific leadership |
| Impact | none yet |
| Start Year | 2023 |
| Description | HDRUK Regional Network and HDRUK London |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK London led a meeting across HDRUK Regional Network to stimulate inter-regional collaboration This included HDRUK North HDRUK Wales, HDRUK South West and HDRUK Midlands. Meetings have focused on our approach to delivering an inter-regional methods pilot focusing on high-cost drug data / climate data. These initial meetings have resulted in grant development meetings and ongoing work to apply for the 2023 NIHR Team Science Award Round 1 - Multiple Long Term Conditions | NIHR grant to take forward work on multi-morbidity and environmental impact of medicines. |
| Collaborator Contribution | Expertise, health data ecosystem and scientific leadership |
| Impact | none yet |
| Start Year | 2023 |
| Description | HDRUK Wales and ELIXIR Network |
| Organisation | ELIXIR |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | UK SeRP (Swansea) has been accepted into the ELIXIR, as part of the UK Node https://elixiruknode.org |
| Collaborator Contribution | health data infrastructure expertise and technical leadership |
| Impact | not yet |
| Start Year | 2023 |
| Description | Human Technopole Collaboration |
| Organisation | Human Technopole |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | Providing samples from UK and Asian cohorts |
| Collaborator Contribution | proteomic assays on our BELIEVE studies, with an kind support value of >3million euro. |
| Impact | None yet |
| Start Year | 2021 |
| Description | International CHD Genetics Consortium |
| Organisation | Central European University |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | The research team have raised funding to assay GWAS, Exome array and CardioMetabochip in most of these participants, brought together the studies and collaborators, collated and harmonised phenotype and clinical data at CEU, coordinated genotyping and data cleaning, formulated and implemented analysis plans. |
| Collaborator Contribution | Provided individual participant data and commented on draft analyses and texts prior to submission of manuscripts for publication |
| Impact | The main outcomes to date are the contribution to discovery of new genetic loci for CHD by subsets of the Consortium. Papers: - IBC 50K CAD Consortium. PLoS Genet. 2011;Sep;7(9):e1002260 (PMID:21966275) - Coronary Artery Disease (C4D) Genetics Consortium. Nat Genet. 2011 Mar 6;43(4):339-44 (PMID:21378988) - The CARDIoGRAMplusC4D Consortium. Nat Genet. 2012 Dec 2 (PMID:23202125) A number of similarly high impact papers are expected to emerge once data from all 100,000 participants have been generated, harmonised and analysed. |
| Start Year | 2010 |
| Description | Joint Webinar: Making a difference: Using Data to Improve Care |
| Organisation | East Midlands Academic Health Science Network |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Developing and delivering a 3 hour online learning event which included speakers from across the UK. |
| Collaborator Contribution | Developing and delivering a 3 hour online learning event which included speakers from across the UK. |
| Impact | Multi-disciplinary collaboration. 163 learners from across the globe. 3 hours of continuing professional development (CPD). |
| Start Year | 2024 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Albert Einstein College of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Baylor College of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Boston University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Brigham and Women's Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Cardiology Frankfurt-Sachsenhausen |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Central Hospital of Bolzano |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Columbia University Medical Center |
| Department | Neurological Institute of New York |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Geisinger Medical Centre |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | German Cancer Research Center |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Harvard University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Helmholtz Association of German Research Centres |
| Department | Helmholtz Zentrum Munchen |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Intermountain Medical Centre |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Johannes Gutenberg University of Mainz |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Malmo University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Mayo Clinic |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Medical University of Innsbruck |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University Medical Center Freiburg |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Cambridge |
| Department | MRC Biostatistics Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Padova |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Rochester |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Texas Southwestern Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Texas Southwestern Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Ulm |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Vermont |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Uppsala University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | Lp-PLA2 Studies Collaboration |
| Organisation | Wake Forest University |
| Department | Wake Forest School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | i) study conception and design; ii) study coordination and management; iii) data acquisition; iv) communication with industry experts and principal investigators of collaborating studies; v) organization of collaborators' meetings; vi) analysis and interpretation of data; and vii) writing relevant manuscripts. |
| Collaborator Contribution | Investigators from 32 prospective studies shared primary data on 79,000 participants |
| Impact | The Lp-PLA2 Studies Collaboration (LSC) has assessed the associations of circulating levels of Lp-PLA2 with vascular disease risk in greater detail than possible previously. Findings from the LSC have helped better characterize the relevance of Lp-PLA2 to vascular risk and were instrumental in helping GlaxoSmithKline to design the STABILITY trial - a phase-III outcome trial of the Lp-PLA2 inhibitor darapladib for secondary vascular disease prevention in 15,000 high risk patients. These findings were instrumental to GSK's decision in 2008 to launch a £250m programme of trials of Lp-PLA2 inhibitors. |
| Start Year | 2007 |
| Description | MELODY study collaboration |
| Organisation | Imperial College London |
| Department | Division of Immunology and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The MELODY study was funded by the MRC and other charity partners (Vasculitis UK, Kidney Research UK, the CF Trust). It was a COVID outcomes study which recruited 28,000 people who were immunosuppressed to investigate their response to COVID-19 vaccination, and outcomes after vaccination. It was conducted in 3 cohorts in parallel: people with rare autoimmune rheumatic diseases, people with lymphoid malignancies, and people who had solid organ transplants. My research team had done the research which made it possible to identify and recruit the cohort with rare autoimmune rheumatic diseases. I led, and my research team in partnership with the National Disease Registration Service conducted the identification, recruitment, data linkage and data analysis for the cohorts with rare autoimmune rheumatic diseases, people with lymphoid malignancies within the National Disease Registration Service. The third cohort, people with solid organ transplants, was conducted using a shared analysis plan within the NHS Blood and Transplant service. |
| Collaborator Contribution | Michelle Willicombe at Imperial College London led the study. NHS Blood and Transplant conducted the data linkage and analysis of the cohort with solid organ transplants. Clinical experts from other universities and NHS Trusts contributed to the planning, interpretation and write up of the project. |
| Impact | 1) Mumford L; Hogg R; Taylor A; Lanyon P; McPhail S; Chilcot J; Powter G; Cooke GS; Ward H; Thomas H; McAdoo SP; Lightstone L; Lim SH; Pettigrew G; Pearce FA*; Willicombe M* (*joint senior authors). Impact of SARS-CoV-2 Spike Antibody Positivity on Infection and Hospitalisation Rates in Immunosuppressed Populations during the Omicron Period: the MELODY study. The Lancet, 2025, 405 (10475) p314-328 DOI: 10.1016/S0140-6736(24)02560-1 2) Pearce FA, Lim SH, Bythell M et al. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY, The Lancet Rheumatology 2023, 5(8) e461-e473 https://doi.org/10.1016/S2665-9913(23)00160-1 |
| Start Year | 2021 |
| Description | NHS England East of England SDE and HDRUK Cambridge |
| Organisation | NHS England |
| Department | NHS East of England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | HDRUK Cambridge are key stakeholders with the East of England sub-national Secure Data Environment; regular meetings ensure join up and coordinated working |
| Collaborator Contribution | expertise, networking |
| Impact | none as yet |
| Start Year | 2023 |
| Description | NIHR Cambridge BRC and HDRUK Cambridge |
| Organisation | National Institute for Health and Care Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDR UK Cambridge researchers have close collaborative links with major cognate initiatives in the Cambridge ecosystem, including the NIHR Cambridge Biomedical Research Centre and the Cambridge BHF Centre of Research Excellence. Additional support is received through both of these initiatives. Professors Inouye and Wood lead the Data Science and Population Science theme of the Cambridge BRC, which brings substantial synergy and added value to HDR UK Cambridge, particularly in the areas of i) the use of biostatistics, machine learning and artificial intelligence (AI) for equitable improvements to healthcare and ii) combining multiple domains of information (such as genetics, imaging, test results and health records) from millions of UK individuals to improve understanding, treatment and prediction of multi-morbidity and disease. |
| Collaborator Contribution | expertise, leveraged funding, collaborations |
| Impact | Numerous collaborative projects and peer reviewed papers |
| Start Year | 2023 |
| Description | NIHR Oxford BRC and HDRUK Oxford |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | HDRUK Programme Manager joint funded by the NIHR Oxford BRC - managing both BRC4 Translational Data Science (TDS) theme and Oxford Regional Network to bring together key health data science efforts across the Oxford region. |
| Collaborator Contribution | Coordination, collaborative working and expertise |
| Impact | none as yet |
| Start Year | 2023 |
| Description | OneLondon LHCRE |
| Organisation | NHS England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Academic and Research Leadership in bringing OnLondon LHCRE together with Luke Readman |
| Collaborator Contribution | £0.9M |
| Impact | Academic, research and clinical outputs |
| Start Year | 2017 |
| Description | Research Data Scotland and HDRUK Scotland |
| Organisation | Research Data Scotland |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The most important partnership HDR UK Scotland is developing is with Research Data Scotland (RDS). RDS is a 5-year initiative to streamline the secure access to health data linked to data from other sectors. We have an existing collaboration with RDS through our HDR UK Scotland work on the Scottish Federated Safe Haven Network, where we have been researching different methods of federated data access and federated analytics. The Scottish site will collaborate closely with RDS, leveraging and enhancing the work of RDS to provide interoperable solutions which can be applied within Scotland and across the UK. Together, we are developing the research data system in Scotland and facilitating data insights to promote and advance health and social wellbeing. |
| Collaborator Contribution | Health data infrastructure expertise, leadership, networking and coordination |
| Impact | none as yet |
| Start Year | 2023 |
| Description | The Cambridge-Baker Systems Genomics Initiative |
| Organisation | Baker IDI Heart and Diabetes Institute |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Contributions include expertise and input from my research team to identify and explore the opportunities for joint research collaboration to 1) meet the next generation of challenges in cardiometabolic disease screening and prevent 2) identification and characterisation of drug targets through multi-omic analysis 3) development of transformational analytic methods that will drive the subsequent research epoch. My group will provide data analysis capacity and training resources to the Baker institute. In the first five year of this collaboration (2018 - 2023), we have provided 50% of employment costs of Prof Inouye, 1 FTE Postdoc position, able to supervise PhD students;, $30,00pa travel support, accommodation and IT facilities for the CBSGI. The collaboration has been extended until 2030, and for the period between 2023 and 2030 we are contributing a total of AUS$4.1million towards salary for professor Inouye and Dr Lambert, a postdoc, admin support and provision of supercomputing. |
| Collaborator Contribution | The Baker Node will provide access to datasets, and other intellectual resources. For the first five year of this collaboration (2018 - 2023) the Baker Node provided 50% of the employment costs of Prof Inouye, 3 x 1FTE postdoc positions, travel support ($30,000 pa), accommodation and IT facilities for the CBSGI, access grant funding to expand capacity. For the extension (2023 - 2030) Baker is contributing a total of AUS$4million towards research staff, allocation from the bioinformatics programme for inter partnership internships for research staff and students, travel costs, and priority access to target validation platform. |
| Impact | Publications: https://doi.org/10.1371/journal.pgen.1007607 https://doi.org/10.1016/j.jacc.2018.07.079 10.7554/eLife.35856 https://doi.org/10.1161/CIRCGEN.118.002234 https://doi.org/10.1093/nar/gky780 https://doi.org/10.1016/j.chom.2018.08.005 https://doi.org/10.1038/s41588-018-0117-9 Committees: Cambridge Baker Experimental Working Group Target validate of in silico discoveries University of Cambridge / Baker Institute Selection Committee: MRC PhD studentships in Data Science / Artificial Intelligence University of Cambridge Symposiums/seminars - Health Data Research UK: Cambridge, Polygenic risk scores and multiple -omics, Cambridge - Alfred Grand Rounds, Genomic risk and precision medicine: Or how I learned to stop worrying and love computational biology, Melbourne - Million Veterans Project Retreat, Integrative omics analysis, Downing College, Cambridge |
| Start Year | 2018 |
| Description | Wellcome Sanger and HDRUK Cambridge |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Human Genetics Department at the Wellcome Sanger Institute has recently proposed to enhance collaboration with HDR UK Cambridge through funding up to three post-doctoral fellows to enhance major synergies between the research endeavours of these groups. The fellows will be jointly supervised by the Sanger Institute and HDR UK faculty. |
| Collaborator Contribution | funding 3 Post doc Fellows, expertise |
| Impact | NA |
| Start Year | 2023 |
| Description | eCamCVD |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am the Chief Investigator |
| Collaborator Contribution | Contributing Scientific expertise |
| Impact | Not yet |
| Start Year | 2023 |
| Title | Anticholinergic Medication Index registered as Class I Medical Device with MHRA |
| Description | Anticholinergic Medication Index (ACMI) to calculate AC medication burden to support better prescribing for patients at risk of adverse outcomes |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | Pilot implementation into SystmOne primary care electronic health record |
| Title | eFI+ |
| Description | eFI+ registered with MHRA as a class I medical device |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Market authorisation |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | Medical device registration |
| Title | eFI+ registered as Class 1 Medical Device with MHRA. |
| Description | eFI+ = series of prognostic models to identify people at increased risk of 1) home care requirement, 2) hospitalisation with falls/fractures, 3) care home admission, 4) mortality. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | As above |
| Title | eFI2 registered as Class I Medical Device with MHRA |
| Description | eFI2 tool to support routine identification of frailty |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Wide-scale adoption |
| Year Development Stage Completed | 2024 |
| Development Status | Under active development/distribution |
| Impact | National policy impact |
| Title | Code and material for IPACS Model - Improving the Flow of Patients between Acute, Community and Social Care |
| Description | The IPACS project was funded by Health Data Research UK. It ran from May 2020-March 2023. The project was undertaken by a research team of six from Bristol, North Somerset, South Gloucestershire Integrated Care Board (BNSSG ICB) (Dr Richard Wood and Dr Paul Forte), University of Bath School of Management (Prof. Christos Vasilakis and Dr Zehra Onen Dumlu) and University of Exeter Medical School (Prof. Martin Pitt and Dr Alison Harper). The IPACS project aimed to investigate what might constitute 'optimal capacity' along different parts of the complex care discharge pathways form acute hospital to community healthcare. The IPACS simulation model is a high-level computer model of the discharge-to-assess (D2A) pathways. It takes a set of input parameters (from an Excel file) and estimates potential future service outputs (occupancy, number of patients with a discharge delay, number of days waiting for discharge, total system costs) based on different configurations of parameters. The model accounts for variation in inputs and outputs, and presents results over time. https://github.com/nhs-bnssg-analytics/ipacs-model |
| Type Of Technology | Software |
| Year Produced | 2023 |
| Impact | • An NHS ICB Business Case cites the IPACS model and its insights. Another ICB is using the tool to inform decision making around resource allocation in the different D2A patient pathways. • We have presented our work to conferences and workshops organised by and for NHS managers and analysts including the annual NHS R conference (https://www.youtube.com/watch?v=RfiuBGD5IeU&t=9789s), and a Demand and Capacity seminar on the as part of the Future NHS network (the recording of the session can be found here but one has to be a member of the Demand and Capacity FutureNHS network to access it). • It has been cited in the 2023 NHS England report on Intermediate care framework for rehabilitation, reablement and recovery following hospital discharge (https://www.england.nhs.uk/wp-content/uploads/2023/09/PRN00761-intermediate-care-framework-rehabilitation-reablement-recovery-following-hospital-discharge.pdf) (S3) • The South West Secure Data Environment (SDE) are using IPACS as one of the two pilot projects of the initiative (https://www.southwestsde.nhs.uk/research/) (S4) |
| URL | https://zenodo.org/record/7845908 |
| Description | BCI Article/Blog - HDRUK North |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Blog published on BCS, Chartered Institute for IT website by HDRUK North Clinical Data Officer role on role of data throughout the pandemic |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.bcs.org/articles-opinion-and-research/cancer-covid-19-and-how-data-saves-lives/ |
| Description | Cohort Discovery Tool Webinar - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | HDR UK Cohort Discovery Tool Webinar taking place on Monday 25th November 2024 at 11.00 am. James Watson, Principal Information Development Manager at Public Health Scotland, will give an overview of the Cohort Discovery Tool https://www.healthdatagateway.org/about/cohort-discovery . He will provide a live demonstration and note any practical tips for researchers. This will be followed by a 15 minute Q&A. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=t-yKZgbyWJI&ab_channel=HDRUK |
| Description | DataLoch Training Webinar - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Planning to use Scottish data in your research? Have you heard of DataLoch but want to know more? Join this session! DataLoch is a data service that has been developed by the University of Edinburgh and NHS Lothian to bring together routine patient data collected as part of people's day-to-day interactions with health and social care services. We will hear about the data hosted by DataLoch and the application process, the most recent developments is the curation of their data, and will discover more about some new data they are adding to the collection. To discover more visit DataLoch website https://dataloch.org/data Speakers: Kathy Harrison, Programme Lead for DataLoch Dr Atul Anand, Senior Lecturer in Health Data Research at the Centre for Cardiovascular Science, University of Edinburgh and Honorary Consultant Geriatrician in Edinburgh. He is the Clinical Lead for DataLoch - the Secure Data Environment for Health and Social Care research in South East Scotland. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=ne0GK8gJDuQ&ab_channel=ResearchDataScotland |
| Description | Developing Data Scientists, National Horizons Centre, Darlington |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA is part of HDRUK North Executive Committee and was part of Developing Data Scientists, National Horizons Centre, Darlington on the 15th March 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Dissemination of COVID-19 vaccination research |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Disseminated COVID-19 vaccination research findings to 12 press outlets via a Science Media Centre briefing and publicity via the University of Cambridge Press office . The research being shared was; DOI:10.1016/S0140-6736(23)02467-4 |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.cam.ac.uk/research/news/significant-gaps-in-covid-19-vaccine-uptake-may-have-led-to-over... |
| Description | Fixing Representation in Genetics: The Place of Ethics in Statistics - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | HDR UK Scotland would like to invite you to a talk by Sasha Henriques, Principal genetic counsellor at Guy's and St Thomas's NHS Trust (GSTT) and PhD candidate with Wellcome Connecting Science, Cambridge University. This will comprise of a 25 minute presentation and 15 minute Q&A. Summary Can objectivity alone ensure authentic, ethical practice? Sasha will talk about her PhD research exploring the place of social justice in genomic research and discuss how data is categorised and how groups like race and ethnicity and even ancestry, if not well defined or understood, can lead to unfair treatment and misunderstandings. Scientists who study genes face a significant challenge: ensuring their findings apply to everyone, not just a few groups. Issues of categorisation, diversity, representation, and sample size can make finding the truth about genes and health harder. Sure, some studies have shown that ideas about race and ethnicity can be harmful. But how do we fix this problem? Are there better categories to use? Should scientists eliminate these categories altogether, or should they use them to make things fairer? How do scientists start thinking about a fair way to study genes? Sasha Henriques Sasha is a principal genetic counsellor at Guy's and St Thomas's NHS Trust (GSTT) and a Ph.D. candidate with Wellcome Connecting Science and Cambridge University, UK. Her doctoral research explores the role of social justice in addressing the structural inequalities in genomic research that arise from the categories of human population descriptors. She is the course director for the GSTT Equity, Diversity and Inclusion (EDI) for Genomic Professionals Training workshop. As a committee member of the Association of the UK Genetic Nurses and Counsellors (AGNC), she was instrumental in convening the association's first EDI subcommittee. Building on her counselling experience in Africa and the UK, she designed and currently delivers cross-cultural communication teaching on the MSc in Genetic Counselling programme at Cardiff University, Wales and the Scientist Training Programme (STP) for genomic counsellors in England. She is active in sharing genetics with all communities, and as such, she co-founded Genetics Engage, a public engagement platform to promote inclusivity in all things genetic. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Guardian interview - Under-vaccinated ethnic minority groups in UK at higher risk of Covid |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Interviewed by Robin McKie, science correspondent for The Observer, about research using whole-population electronic health records, featured in The Observer |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.theguardian.com/world/2024/oct/27/undervaccinated-ethnic-minority-groups-in-uk-at-higher... |
| Description | HDR Integration Meeting Held in London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Professor Sir Munir Pirmohamed and Professor Andy Clegg gave an overview of HDRUK North Regional Activities & Opportunities for Integration. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR London - Presentationto HDRUK Board |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Presentation to HDR UK Board on 26 Sept 2024 on high cost drugs (Langan), retinal imaging analyses (Keane), Atlas for Health (Hemingway) and Foresight (Tomlinson) Generative AI approaches at nationwide scale and Atlas for Health Foresight is a general-purpose model for biomedical concept modelling that can be used for real-world risk forecasting, virtual trials, and clinical research to study the progression of disorders, to simulate interventions and counterfactuals, and for educational purposes. Atlas for Health seeks to leave no person and no disease behind. It offers a comprehensive approach to learning how to improve our nation's health. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Annual Conference, Leeds |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | HDR North was involved in HDR UK Annual Conference, Leeds on 5th and 6th March 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Cambridge Seminar Series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Project team organise monthly seminar series (in hybrid format), with domain-leading experts presenting across a range of interconnected disciplines, including machine learning, wearable devices, hospital data, genetics for therapeutic target identification. Main goals are to foster new nation wide collaborations and exchange an existing knowledge. Speakers have included representatives of other HDR UK regions and programmes (e.g. Jonathan Sterne, Reecha Sofat) and representatives of biotechnology/pharmaceutical companies (e.g. Peter Wurtz from Nightingale Health). Seminars have fostered new collaborations with HDR UK Cambridge researchers and invited speakers from other regions, for example with Professor Aiden Doherty around wearable devices. |
| Year(s) Of Engagement Activity | 2022,2023,2024 |
| Description | HDR UK London - IMID Data Catalyst Workshop |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | workshop which brought together a wide range of stakeholders including patients, charities, researchers and clinicians with a special interest in immune mediated inflammatory diseases, health data experts and regulatory bodies to discuss the key ambitions and opportunities in health and care data to deliver benefits for patients with Immune Mediated Inflammatory Diseases (IMIDs). Addressing the need to move away from siloed care and research, we formed a collaborative group emerging from the pandemic Immune Mediated Inflammatory Disease Taskforce and devised a workshop in partnership with Health Data Research UK (HDR UK). The goals of the workshop were to bring together a wide community of stakeholders to identify what the key barriers and priorities were in terms of data access and linkages to enable transformative research which will ultimately lead to better patient outcomes. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://zenodo.org/records/10789451 |
| Description | HDR UK Meta-Sprint Technology Meeting Held in Liverpool |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | An in-person workshop hosted by the Health Data Research UK technology team was held at the University of Liverpool. The workshop focused on how the gateway, cohort discovery, phenotype library, and disease atlas can create value and integrate with the work of the regional team. There was also a discussion on the opportunity for co-creating a tech solution together. The regional presentation was delivered by Adrian Jonas, Chief Analyst for the Northwest Region NHS England (Northwest SDE), and Technical Specialist for the Northwest Region NHS England. The visit to the Civic Health Innovation Labs was led by Professor Iain Buchan, Director of the Civic Health Innovation Labs (CHIL) at the University of Liverpool. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Midlands Launch Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Regional Launch Event: Held in Birmingham 4th July 2023. 69 People attended from across the Region. Presentations from 3 regional NIHR Biomedical Research Centres (Birmingham, Leicester, Nottingham). Presentations from the 2 regional Secure Data Environments (SDEs) (East and West Midlands SDEs). |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDR UK Midlands Monthly Science Meetings: Promoting Knowledge Exchange |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Five HDR UK Midlands Data Grand Round science-sharing webinars have been held, attracting 158 participants. These monthly meetings provide a vital platform for scientific collaboration and the exchange of cutting-edge health data insights. Quarterly insight sharing webinar [Using AI Responsibly] developed in collaboration with the NIHR-Supported Incubator for AI and Digital Healthcare. Webinar held in October 2024 with > 200 participants attending from across the globe. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.hdrmidlands.org.uk/data-grand-round/ |
| Description | HDR UK Midlands Training and Learning Initatives |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | A total of 415 individuals were trained through 12 events organised by HDR UK Midlands, highlighting a strong commitment to skills development and capacity building. b) HDR UK Midlands' learning content has been shared on the HDR UK Futures platform, further extending its reach and impact in health data education. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.hdrmidlands.org.uk/past-events/ |
| Description | HDR UK Midlands conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The HDR UK Midlands Annual Conference held in Nottingham on 13th July 2024 was a landmark event, attracting 150 key stakeholders from across the region. The conference featured high-profile presentations, including Andrew Morris, local NHS CEOs, leaders from three regional NIHR Biomedical Research Centres (Birmingham, Leicester, Nottingham), both the East and West Midlands Secure Data Environments (SDEs), and the HDR UK Training Team. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.hdrmidlands.org.uk/hdrevents/hdr-uk-midlands-annual-conference-13-jun-2024/ |
| Description | HDR UK North & Trials Methodology Research Partnership (TMRP) Patient-Reported Outcomes (PROs) Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | online workshop which was held to discuss what needs to be done to make patient-reported outcomes part of routinely collected health data. Researchers and patient/public in attendance. The aims of the workshop were to consider how PROs could be embedded into routine care to improve care and research. Highlight key areas in the field and identify opportunities and challenges to feed future |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDR UK North Executive Committee |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | Co- directors Professor Sir Munir Pirmohamed and Professor Andy Clegg chair the HDR UK North Executive Committee on a quarterly basis. The Executive Committee are supposed to work in collaboration to help deliver the regional objectives. These meetings are also an opportunity for our co-directors to update members on developments to encourage key discussions within the region. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Regional Quarterly Network Meetings |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Led by the HDR UK national team, these meetings are held quarterly to enable the exchange of ideas and synthesise cross-community, priority activities. Also, to share details on regional activities and challenges. Regional network manager for HDR UK North has attended these meetings on behalf of the region. |
| Year(s) Of Engagement Activity | 2021 |
| Description | HDR UK Regional Quarterly Network Meetings |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Led by the HDR UK national team, these meetings are held quarterly to enable the exchange of ideas and synthesise cross-community, priority activities. Also, to share details on regional activities and challenges. Regional network manager for HDR UK North has attended these meetings on behalf of the region. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Scotland and the Chief Scientist Office (CSO) joint webinar - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This is a joint webinar between HDR UK Scotland and the Chief Scientist Office (CSO). This webinar will give an introduction to both the CSO is and the CSO fellowship programme. We will hear from the following speakers: Katie Wilde (Chair), co-director of HDR UK Scotland Katie will provide an introduction to the webinar, and discuss the agenda for the event. Professor David Lowe, Clinical Lead for Innovation In this Presentation, David Lowe will provide a short introduction covering the CSO strategic vision. Sean Anderson, Senior Policy and Programme Manager 'Chief Scientist Office Overview and Innovation Fellowships' In this presentation, Sean Anderson will give a short overview of the Chief Scientist Office and the CSO Innovation Fellowship Programme. Chris Sainsbury, Innovation Fellow 'Generating Conditional Synthetic Data for Trial Emulations' In this presentation, Chris Sainsbury will discuss his current research. Here, he is using a machine learning methodologies (generative adversarial neural networks, and a conditional variational autoencoder) to produce synthetic populations of individuals from routinely-collected Electronic Health Record data. From this, the effect size of therapeutic interventions of interest can be estimated. Following the presentations, there will be an opportunity for a Q&A with the speakers. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDR UK Wales delivery of PRIMORANT webinar |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Delivery of PRIMORANT webinar to Trials Methodology Research Partnership in Oct 2023 https://www.tmn.ac.uk/events/tmrp-webinar-how-can-trial-teams-build-public-trust-for-the-use-of-routine-data |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Midlands Chief Clinical Information Officers' Network |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Midlands Chief Clinical Information Officers' Network is a regional community of CCIOs from NHS organisations across the East and West Midlands regions of the UK. 60 members from 52 organisations. 3 monthly network meetings held within period. Presentations from 2x CCIOs, the two regional Imaging Networks (NHS England), and presentations and discussion with our 2 regional NHS England Secure Data Environments (SDEs). |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.hdrmidlands.org.uk/ccio-network/ |
| Description | HDRUK Midlands Regional Community Platform |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The HDR UK Midlands Regional Community Platform serves as as a key enabler for collaboration and engagement in health data research. Its ongoing development reflects its increasing importance as a central hub for the region's health data ecosystem. The HDR UK Midlands Regional Community has grown to over 500 members from 64 organisations, with 302 stakeholders registered as honorary members. This expanding network fosters greater egional collaboration, knowledge sharing, and cross-organisational engagement. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.hdrmidlands.org.uk/ |
| Description | HDRUK Midlands Training Sessions/Workshops |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Training courses have trained 49 people trained via 7 events organised by HDR UK Midlands. Monthly Science Meeting: 5 Monthly Data Grand Round meetings held (science sharing webinars). 208 participants attended. Insight Sharing: 1st Quarterly insight Sharing Webinar held (17th October 23). 272 participants joined from across the globe. Topic: Health Inequalities and Diversity in Health Data Science. Presentations included talks from our Early Career Researchers (ECRs), and HDR UK Black Internship Programme. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.hdrmidlands.org.uk/past-events/ |
| Description | HDRUK North - Better Care Insights Sharing Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | HDR UK Midlands led this event as the national Better Care lead and HDR UK North provided a showcase on the following projects: Su] 'Digital Care Homes' project, ]] 'Better-antibiotic prescribing for frail elderly people' project and 'optimising anticholinergic medication prescribing' project. HDRUK North co lead attended and presented on the HDRUK Medicines in Acute and Chronic Care Driver Programme. |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK North led TRE/SDE survey |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | HDRUK North developed live online survey open to gather information to enable us to catalogue TREs, SDEs and FDPs across the North of England. This exercise will link into HDR UK's Pillar 1 infrastructure programme and facilitate data sharing across multiple systems for regional and national gain. It is anticipated that this work will reach completion in May 2024 which is a 3-month extension to our original timeline. Once this work is complete it will give us a much clearer picture of the health data assets held in the North, it will be shared widely and will open opportunities for engagement with these platforms. |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Oxford Data Science Training Sessions |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | HDRUK Oxford leads delivery of scientific training in health data science. The first two sessions scheduled this term, focus on accessing and use of Clinical Practice Research Datalink data. We have also arranged a termly 'Medical statistics drop in session' and regular informal meetings for data engineers in aimed at building a community for people working in the space between data generation and analysis |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Oxford seminar series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | 10 seminars and events held in total between October and December 2023 attracting attendees from more than 17 departments across the University. Events providing insight into industry have been of particularly high interest. Events included 'Leadership in the life sciences'. We also held a seminar from DeepMind on 'Accurate proteome-wide missense variant effect prediction with AlphaMissense'. Both events were fully subscribed with >100 attendees. Other events include seminars as part of the regular BDI 'Genomics' and 'Phenome' series that include both internal and external speakers. |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Oxford seminar series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | We continue to host a programme of events around applied health data science. This enables us to convene researchers across the Oxford region, promote knowledge transfer and dissemination of research, so facilitating collaboration and building community. Over 20 seminars and events were held during this period, which included introductory training workshops on Clinical Practice Research Datalink (CPRD), Data Engineers meetings and the one-day HDRUK Regional Community meeting, which are held in a hybrid format when feasible. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK SW Seminar : December 2024 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of current health data science related work - in this case with real world application - with opportunities for discussion and potential generation of new collaborative research ideas. Title: Use of applied research to support Demand and Capacity modelling in the BNSSG healthcare system Speaker: Richard Wood Institution: NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board Abstract: In many ways, the NHS is just a system of queues, whose timing and magnitude depends on the balance between demand and capacity. Queueing time affects patient experience and outcomes and is routinely measured against key performance metrics, e.g., the 4-hour ED target. Quantifying the impact to these performance metrics of possible decisions relating to demand and capacity is important for effective healthcare management. To this end, computational modelling and scenario analysis can be a valuable asset. Yet, many problems in the healthcare domain are complex, and can require equivalently sophisticated solutions. This and the numerous gaps in the scientific literature combine to provide a rich environment for novel applied research. In this talk, I will provide some examples of how we have approached Demand and Capacity modelling for applied research initiatives in the Bristol, North Somerset and South Gloucestershire healthcare system. I will end by discussing the potential for related undertakings given the forthcoming publication of the NHS's 10 year plan. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK SW Seminar June 2024 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Academics from across the SW region presented recent health data science related work with opportunities for discussion and potential generation of new collaborative research ideas. Talks included: Title: The rise of the secure data environment: learnings from national and regional resources Speakers: Rachel Denholm and Venexia Walker Institution: University of Bristol Abstract: The COVID-19 pandemic provided the opportunity for unprecedented access to national electronic health record data for research in secure data environments. At the same time, there has a been a push to develop regional secure data environments that contain the granular information collected more locally. Jonathan Sterne, Rachel Denholm and Venexia Walker co-lead a team of researchers at the University of Bristol who have worked within these environments. During this seminar, Rachel and Venexia will share their learnings and future directions for research using these resources. Title: A comparison of methods for externally validating the Kidney Donor Risk Index in the UK kidney transplant population Speaker: Stephanie Riley Institution: University of Plymouth Abstract: Transplantation represents the optimal treatment for many patients with end-stage kidney disease. The Kidney Donor Risk Index (KDRI) was developed to predict graft failure following kidney transplantation. The survival process following transplantation consists of semi-competing events, where recipient death precludes graft failure but not vice-versa. We sought to externally validate the KDRI in the UK kidney transplant population, and assess whether validation under a competing risks framework had an impact on predictive performance. Additionally, we updated the KDRI using data from the United Kingdom to explore whether this improved the predictive performance. |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK Scotland AI and Healthcare online event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | AI and healthcare online event held to anticipate advances in technologies that are on the horizon and discuss the impact these may have on our research over the quinquennium Event recording Event recording https://www.youtube.com/watch?v=NiFRm6Fp14A |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK Scotland - SafePod Network seminar |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | After liaising with the SafePod Network, a webinar was held to increase awareness and adoption in Scotland and accelerate access Event recording https://www.youtube.com/watch?v=bmLRkGVaPqY The SCADR network published a blog post about SafePods and HDR UK Scotland https://www.scadr.ac.uk/news-and-events/blog-reflections-safepod-network-and-hdr-uk-scotland-webinar |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK Scotland Orkney Science Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | HDR UK Scotland were involved in Orkney International Science Festival. This included chairing the conversation session 'Health from data?' at the Orkney Theatre. This was also recorded for the festival's YouTube Channel |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://oisf.org/ |
| Description | HDRUK Scotland Quarterly Meetings |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Quarterly HDRUK Scotland meetings that bring together the relevant stakeholders and HDRUK leadership across HDRUK Scotland. Recent meetings have included DARE UK Project presentations and Research Data Scotland updates |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK South West Training and capacity building in health data research in SW region |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | South West Analytics and Infrastructure in Healthcare (SWAIH) was held in Exeter in July 2023. The event was attended by 142 participants from over 40 NHS and academic organisations across the South West. The organisation of a second SWAIH event, held in Exeter on 9th July 2024, is underway. Plan to map relevant health data science training courses across South West academic Institutes underway. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://sites.google.com/nihr.ac.uk/swaih/home |
| Description | HDRUK South West Seminar Series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The seminar series was open to all and showcased a range of topics in health data research, from using big data from electronic health records and national registry databases to demand and capacity models and the reproducibility of simulation models for healthcare delivery. |
| Year(s) Of Engagement Activity | 2024,2025 |
| Description | HDRUK South West Training seminars and series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Regional seminar series initiated, first seminar on using big data from health records took place virtually in June 2024, with a recording made available for use on HDRUK Futures training platform. South West Analytics and Infrastructure in Healthcare (SWAIH) was held in Exeter in July 2024. The event was attended by 150 participants from over 45 NHS and academic organisations across the South West. Resources from the meeting, including programme and slides are available on the SWAIH website. We anticipate that SWAIH will continue as an annual regional event. The University of Bristol short course 'Analysing data in TRE' ran as a pilot in April 2024. The course has been added to the Bristol Medical School short course programme for external applicants. Delivered training workshops at HDR conferences/events ('Producing analysis-ready datasets in TRE/SDE settings' at HDR UK early career researcher workshop, September 2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | HDRUK Wales article in the Conversation |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Article published in The Conversation magazine: Linking police and healthcare data could help better identify domestic abuse - new research https://theconversation.com/linking-police-and-healthcare-data-could-help-better-identify-domestic-abuse-new-research-208986 |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Wales delivery of TOPCAT webinar |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Presentation of TOP-CAT (name of Cardiff-led component of HDRUK Transforming Data for Trials workstream to Treialon Cymru webinar July 2023 |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Wales presentation at Our Future Health |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation given at Our Future Health Science and Strategy Day |
| Year(s) Of Engagement Activity | 2023 |
| Description | HDRUK Wales presentation to Violence and Society Centre |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation given for the Violence and Society Centre (UK wide organisation) on following project: insights from linking police domestic abuse data and health data in South Wales, UK: a linked routine data analysis using decision tree classification |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00126-3/fulltext |
| Description | Health Data Round Table event, Durham University |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA was involved as part of HDRUK North for Health Data Round Table event, Durham University on the 27th March 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Human Genetics Retreat |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Reviewing collaboration, innovation and leadership activities of Human Genetics Group |
| Year(s) Of Engagement Activity | 2023 |
| Description | Is "Winter pressure" on urgent and emergency care now seen all year? |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Blog informed readers and scientists on how Winter pressures are currently manifesting in features of ED attendances and acute hospital admissions. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Launch of HDRUK Oxford webpage |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | https://www.bdi.ox.ac.uk/upcoming-events/hdruk-oxford-regional-community-event Launch of HDR Oxford webpage to drive engagement across the Oxford Region in data science capacity buidling, seminars etc. Has helped share relevant information and support the community. Currently we have over 160 subscribers to a mailing list also from various departments at Oxford (e.g. Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Nuffield Department of Primary Care Health Sciences) as well as other organisations and beyond in the region including Oxford Brookes University, University of Reading, Oxford University Hospitals, University of Edinburgh, University of Glasgow, University of Malaysia, University of Indonesia and a South American compan |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.bdi.ox.ac.uk/research/hdr-uk |
| Description | MRC Community Visit for the North of England - Day 2 inc. Health Data Theme, Leeds |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | MRC Community Visit for the North of England - Day 2 inc. Health Data Theme, Leeds on 4th of June 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Media engagement around the environmental impacts of computing, Loic Lannelongue |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Media coverage in the Times Higher Education, Physics World and other newspapapers. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://physicsworld.com/a/researchers-issue-warning-over-the-increasing-carbon-footprint-of-computa... |
| Description | Media engagement around the environmental impacts of computing, Loic Lannelongue |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | interview with BBC radio/The Naked Scientists in January 2023 and June 2023 (recorded and broadcasted live and also released as a podcast). Media coverage in the Times Higher Education, Physics World and other newspapapers. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.thenakedscientists.com/articles/interviews/calculating-computers-carbon-footprint |
| Description | Methods for the Economic Evaluation of Diagnostics, Digital, Data and Devices (MEED) Research Forum - Diagnostics, Data, Digital and Devices |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA as part of HDRUK North was involved in Methods for the Economic Evaluation of Diagnostics, Digital, Data and Devices (MEED) Research Forum - Diagnostics, Data, Digital and Devices (see: https://meedhta.wpcomstaging.com/), Newcastle Helix on 28th of November 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | NortHFutures Digital Health Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA was involved in NortHFutures Digital Health Symposium (see: https://www.northfutures.org/posts/northfutures-digital-health-symposium-2024/), Sunderland on 7th October 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | NortHFutures Strategic Advisory Board Meetings |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | NortHFutures Strategic Advisory Board Meetings with NHSA involved in meeting on 17th May 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | North West Secure Data Environment Meetings, Online |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | North West Secure Data Environment Meetings. Online meetings occurred with NHSA on 27th March, 3rd June, 17th June, 17th July, 6th August, 3rd September, 17th September, 3rd October, 17th October, 18th November 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | One Day Regional Community Meeting -HDR UK Oxford |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | To strengthen existing activities and promote new collaborations and opportunities, we organised and hosted a one-day Regional Community Meeting in September, with the intention of making this annual occurrence. Prof Sir Aziz Sheikh was our keynote speaker and we also showcased work in the Dementia Trial Accelerator (DTA), the Thames Valley & Surrey NHS secure data environment, the Planetary Health Informatics programme, Real-World Evidence, various data driven clinical trials, observational studies and our work round Patient and Public Involvement and Engagement (PPIE). Early Career Researchers had the opportunity to promote their work by displaying posters. This hybrid event was extremely successful with just under 200 registrations (around 70 virtually) from a wide range of organisations. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Online seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This talk introduces the IPACS project - exploring how to optimize capacity for complex patient discharge pathways and understand how to alleviate the shortage of acute beds that results from any delays in discharge to social care . Transferring patients from hospitals to their homes or temporary care facilities is a complicated process that requires both efficient planning and effective support. However, delays and capacity issues often disrupt this process, especially when there isn't enough care available in the right place at the right time. Social care shortages, as the final step in the care chain, are a major contributor to these delays. In 2019 alone, delays caused by unavailable social care led to the loss of about 500,000 acute hospital bed days in England. Researchers from the Universities of Bath and Exeter collaborated with healthcare managers in local NHS Trusts to create an open-source simulation tool coded in R. This adaptable and free tool models discharge pathways, known as 'Discharge to Assess' (D2A), and helps predict demand, capacity, and patient stay durations. By simulating scenarios, it can directly support decision-making for improving D2A services and managing seasonal pressures like winter demand. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://sites.google.com/nihr.ac.uk/swaih/home/insight-talks/ipacs |
| Description | Participation in HDRUK Driver Programme and Infrastructure Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Participation in the HDR UK Driver & Infrastructure Scientific Meeting and break out meeting of the HDR Inter-Regional Collaboration 1 May 2024 . Opportunities for cross-region collaboration were discussed at in-person event |
| Year(s) Of Engagement Activity | 2024 |
| Description | Putting the Practice into Policy - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | a talk by Dr Mavis Machirori, Senior Researcher at the Ada Lovelace Institute. This will comprise of a 25 minute presentation and a 15 minute Q&A. This talk will be a reflection and retelling of Mavis' journey from clinical practice to policy research, which will touch on career pathways, progression and conundrums! Mavis will talk about serendipitous moments and intentional decisions - and how they have led to the research she is currently working on. She looks forward to having a lively discussion about what it means to be using all of you and your knowledge in different spaces. You can find out more about Mavis on her LinkedIn: https://www.linkedin.com/in/mavis-machirori/ |
| Year(s) Of Engagement Activity | 2024 |
| Description | Research Data Scotland, Researcher Access Service Accelerator Award Showcase - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Research Data Scotland (RDS), along with Health Data Research (HDR UK) Scotland, are hosting a webinar on Wednesday 4th December (13:00 - 14:00) which will be open to anyone who would like to learn more about the Researcher Access Service. This event will be online only and will take place via Microsoft Teams. A link to access the webinar will be provided to ticket holders closer to the event date and the session will be recorded for anyone who is unable to attend on the day. This webinar will include: An intro from HDR UK Scotland co-Director - Katie Wilde a presentation by RDS digital and data teams, including details of datasets available via the Researcher Access Service, useful information for prospective applicants, updates on how it has progressed since launch and future plans for the service, a presentation from one of the Accelerator Award funded researchers on their experience with the Researcher Access Service application process and the progress made on their research project so far, a detailed demonstration of the application process, a Q&A session for attendees to ask any questions they might have. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Researcher Data Access Service workshop (HDRUK Scotland) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Researcher Access Service Workshop held with HDR UK Scotland and Research Data Scotland (RDS) to discuss the new researcher access service for the Scottish National Data Safe Haven. This workshop provided an introduction to RDS and will focus on the Researcher Access Service which will launch early 2024 with initial health datasets. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.researchdata.scot/our-work/current-projects/researcher-access-service/ |
| Description | South Yorkshire Digital Health Hub Collaboration Board Meetings |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA was part of the South Yorkshire Digital Health Hub Collaboration Board Meetings 25th September 2024 and 12th December 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | Talk at the HDRUK Leadership and Strategy Retreat on "COVID-19, Cardiovascular Events, and Cancer Risk Prediction." (Sam Ip) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The event brought together over 70 individuals across the HDR UK network. Event aim was to network, discuss strategic priorities and give spotlight to Early Carrier researchers. |
| Year(s) Of Engagement Activity | 2023 |
| Description | The ATLAS of Longitudinal Datasets - A New Discoverability Tool for Longitudinal Research - HDR UK Scotland |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | a webinar showcasing The Atlas of Longitudinal Datasets; a groundbreaking web-based, searchable platform that maps thousands of longitudinal datasets from around the world. This session is a unique opportunity for researchers, data scientists, and professionals in the field of longitudinal studies to explore how the Atlas can enhance the discoverability and facilitate accessibility of longitudinal data across key scientific disciplines such as mental health, physical health, education, and linked administrative data. Attendees will get a first-hand look at the platform's innovative features through live demonstrations, interactive Q&A session, and insights into its application in research. The event will also highlight the significance of the Atlas in bridging gaps and facilitating new research directions. Agenda: 12.00 - Introduction by Katie Wilde (HDR UK Scotland Co-Director) 12.05 - Presentation by Professor Louise Arseneault (Professor of Developmental Psychology) 12.25 - Demonstration by Bridget Bryan (Research Assistant & PhD Candidate) 12.45 - Q&A Why Attend? This is a special opportunity to be among the first to experience the Atlas, a platform designed to amplify longitudinal data discoverability. Gain direct insights into how this tool can support your research, uncover new datasets, and provide invaluable resources for future studies and grant applications. You can find out more about the organisation here: https://atlaslongitudinaldatasets.ac.uk/ |
| Year(s) Of Engagement Activity | 2025 |
| Description | UKRI STFC Daresbury Data Conference |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | NHSA is part of HDRUK North Executive Committee and was involved in UKRI STFC Daresbury Data Conference, Hartree Centre on 23rd of January 2024. |
| Year(s) Of Engagement Activity | 2024 |
| Description | UKRI STFC Daresbury Data Conference, Hartree Centre |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | UKRI STFC Daresbury Data Conference, Hartree Centre. NHSA was engaged with this as part of HDRUK North. |
| Year(s) Of Engagement Activity | 2024 |